4-Methylumbelliferone (4-MU)

Catalog No.S2256

Molecular Weight(MW): 176.17

4-Methylumbelliferone is a hyaluronic acid (HA) synthesis inhibitor with an IC50 of 0.4 mM.

Purity & Quality Control

Biological Activity

Description

4-Methylumbelliferone is a hyaluronic acid (HA) synthesis inhibitor with an IC50 of 0.4 mM.

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
COS1 cells	M4nIOWZ2dmO2aX;uJIF{e2G7			NHjwbmVC\2:waYP0bYMh[WO2aY\peJkhf2G\|IHTleIVzdWmwZXSgbY4hS0:VMTDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKEeDTDC0MXBRSVJiZ3HtcYEhemWlZYD0c5ItKEWFNUC9NE4xOjFizszN	M1PPNVEzPjF5OUK0
CV-1 cells	MmHoSpVv[3Srb36gZZN{[Xl?			NEjQSJhO[XirbXHsJJJmeG:{dHXyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUHXyc5hqe2:vZTDwdo9tcW[ncnH0c5Ih[WO2aY\heIVlKHKnY3XweI9zKGejbX3hJGdidDRiY3jpcYVzcWNiaX6geJJidnOrZX70cJkhfHKjboPm[YN1\WRiQ2[tNUBk\WyuczDifUBnfW6ldHnvcoFtKGG\|c3H5MEBGSzVyPUCuNFQ{KM7:TR?=	NXXSNoVpOTF5MkC4OVQ>
COS-1 cells	M3Hte2Z2dmO2aX;uJIF{e2G7			NHrVeGtKdiC4aYTyc{B1emGwc3HjeIl3[XSrb36gc4YhcHWvYX6gdIVzd3irc3;t[UBxem:uaX\ldoF1d3JiYXP0bZZifGWmIILlZ4VxfG:{IHfhcY1iKG2nYYP1doVlKGmwIGDQRXIuT0GONDDjbIlu\XKrYzDDU3MuOSClZXzsd{whTUN3ME2wMlAzKM7:TR?=	NYjWcmZPOTJ6N{O1NVc>
CV-1 cells	NXnQR\|EyTnWwY4Tpc44h[XO\|YYm=			MYDBZ5RqfmG2aX;uJI9nKHCncn;4bZNwdWVicILvcIln\XKjdH;yJIFkfGm4YYTl[EBz\WOncITvdkBo[W2vYTDt[YF{fXKnZDDifUBqdmS3Y4Tpc44hd2ZiNUClJI9nKG2jeHnteY0h[WytYXzpcoUheGixc4DoZZRie2ViYXP0bZZqfHluIITyZY5{\mWldHnvckBie3OjeTDpckBEXi1zIHPlcIx{NCCHQ{WwQVAvODh7MUOg{txO	M{GzZlk5OzZ4MkC=
CV-1 cells	M3;DSmZ2dmO2aX;uJIF{e2G7			MVXJckB3cXS{bzD0doFve2O{aYD0bY9v[WxiYXP0bZZifGmxbjDv[kBR\XKxeHnzc41mKHC{b3zp[oVz[XSxcjDhZ5RqfmG2ZXSgdoVk\XC2b4Kg[4FudWFiKGDQRXIqKGW6cILld5Nm\CCrbjDDWk0yKGOnbHzzMEBGSzVyPUCuNFYh\|ryP	NF\GVW05PTd4OUC3
COS-1 cells	NEXlV5VHfW6ldHnvckBie3OjeR?=			MoOwTY4hfmm2cn:gZYdwdmm\|dDDhZ5Rqfmm2eTD0[ZN1\WRiZn;yJJRz[W6\|YXP0bZZifGmxbjDpckBpfW2jbjDQVGFTKGejbX3hMWdidDRiY3jpcYVzcWNiQ1;TMVEh[2WubIOsJGVEPTB;MD6wNkDPxE1?	M4XNbVEzPzJ7Nk[4
CV-1 cells	MXfGeY5kfGmxbjDhd5NigQ>?			MkmzTY4hfmm2cn:g[ZZidHWjdHnvckBi\2GrboP0JHJZWi2jbIDoZU9RWEGULXfhcY1iKGmwIFPWMVEh[2WubIOgZpkh[2:2cnHud4Zm[3Srb36gZZN{[Xlid3HzJIRmfGW{bXnu[YQtKEWFNUC9NE4{OjVizszN	M4XCS\|EzQTV2ME[x
HepG2 cells	NWLsO\|R2TnWwY4Tpc44h[XO\|YYm=			MVnF[oZm[3SrdnWgZ49v[2WwdILheIlwdiCjZ3HpcpN1KGi3bXHuJHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iSHXwS\|Ih[2WubIOsJGVEPTB;MD6wN\|kh\|ryP	NWr1UG5KOTZzMEexOVA>
Huh7 cells	NWH3fmlJTnWwY4Tpc44h[XO\|YYm=			MlvFSpVv[3Srb37hcEBi[3Srdnn0fUBifCCqdX3hckBRWEGUIHfhcY1iKGmwIFj1bFch[2WubIOgZpkhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxRTBwMkKg{txO	MoLuNVY{PjZ4MEG=
Huh7 cells	MUDGeY5kfGmxbjDhd5NigQ>?			M1TWXWVn\mWldDDvckBRWEGUIHfhcY1iKHS{YX7zZYN1cX[jdHnvckBi[3Srdnn0fUBqdiCKdXi3JINmdGy\|LDDFR\|UxRTBwMkKg{txO	MVKxOlQ2OTB6Nx?=
U2OS cells	M2fLWWZ2dmO2aX;uJIF{e2G7			MVPF[oZm[3Rib36gVHBCWmejbX3hJJRz[W6\|YXP0bZZifGmxbjDhZ5Rqfmm2eTDpckBWOk:VIHPlcIx{NCCHQ{WwQVAvODNizszN	NWDXZ2syOTZ\|MEC5OFQ>
CV1 cells	M4jlVmZ2dmO2aX;uJIF{e2G7			NHXoTHhVemGwc3HjeIl3[XSrb36gc4YhWFCDUnfhcY1iKGmwIFPWNUBk\WyuczygSWM2OD1yLkC3OkDPxE1?	MkPENVY5OjF5Nkm=
human keratinocytes	M2q2b3Bzd2yrZnXyZZRqd25iYYPzZZk>			NGP2PXdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIHvldoF1cW6xY4n0[ZMtKEWFNUC9PEDPxE1?	M1HsWlE3QDJzN{[5
HT29 cell	M1fhfnBzd2yrZnXyZZRqd25iYYPzZZk>			M4mwXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGSyPUBk\WyuIHzpcoUtKEWFNUC9OFUh\|ryP	NEPhXYcyPjh{MUe2PS=>
NIH3T3 cells	MX3GeY5kfGmxbjDhd5NigQ>?			NYfNUIVnSWO2aY\peJkh[XRiaIXtZY4hWFCDUjDnZY1u[SC2cnHud4Zm[3SnZDDpckBPUUh\|VEOgZ4VtdHNiYomgcJVkcW[ncnHz[UBi[3Srdnn0fUBie3OjeTygSWM2OD1yLkOyJO69VQ>?	M{HpR\|E3QDV2MEi1
CV1 cells	NYXsVm1uTnWwY4Tpc44h[XO\|YYm=			MnjzWJJidnOjY4TpeoF1cW:wIH;mJIh2dWGwIGDQRXJo[W2vYTDpckBEXjFiY3XscJMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBGSzVyPUCuN\|A5KM7:TR?=	NFHHZVUyPjl5MEO5NS=>
Huh7 cells	MU\GeY5kfGmxbjDhd5NigQ>?			M4rwc2FkfGm4aYT5JIF1KGi3bXHuJHBRSVJiZ3HtcYEhcW5iSIXoO{Bk\WyuczDifUB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5{MjFOwG0>	NEH0XIQyPzB\|NEG0PS=>
HepG2 cells	Mn7oSpVv[3Srb36gZZN{[Xl?			MoLzRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFTKGejbX3hJIlvKGFiSHXwS\|Ih[2WubIOgZpkhWFCDUj3HRWw1KHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1yLkG1PEDPxE1?	M3\lTlE3QTd\|M{W4
HepG2 cells	MXzGeY5kfGmxbjDhd5NigQ>?			M1vFUWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWiCpYX3tZUBqdiCKZYDHNkBk\WyuczDifUBRWEGULVfBUFQhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxRTBwMUW4{txO	M4XXNFE3QTd7M{Sx
CV1 cells	M{jDNGZ2dmO2aX;uJIF{e2G7			M3fDTWFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZUBqdiCFVkGgZ4VtdHNuIFXDOVA:OC5\|MEig{txO	MXqxO\|AxPTN7NB?=
HEK293 cells	M{\OU2Z2dmO2aX;uJIF{e2G7			NUTnbVNxSWO2aY\peJkh[XRiaIXtZY4h[WSrcH;z[UB1cXO\|dXWgVHBCWiCpYX3tZUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIJ6KFCSQWKtS2FNPCC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;MD6zNUDPxE1?	MXWxO\|M1OzN5MR?=
rat L6 cells	NELXb5JHfW6ldHnvckBie3OjeR?=			MXPF[oZm[3Rib36g[oF1fHliYXPp[EBwgGmmYYTpc44hcW5icnH0JGw3KGOnbHzzMEBGSzVyPUWg{txO	M4rXNFE4OzR\|M{ex
HepG2 cells	MVzGeY5kfGmxbjDhd5NigQ>?			M2DmW2Fod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJIlvKEincFeyJINmdGy\|IHL5JHBRSVJvR1HMOEB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5yOEKg{txO	MV:xO\|E2PzBzOR?=
CV1 cells	M1LZXGZ2dmO2aX;uJIF{e2G7			NYni[W9{SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUYXzwbIEhcW5iQ2[xJINmdGy\|IHL5JGdCVDRidILhcpNi[3SrdnH0bY9vKGG\|c3H5JIFnfGW{IEK0JIhzeyxiRVO1NF0{NjR4IN88US=>	NFzFXYUyPzVyN{KyOS=>
CV1 cells	NFHWPVFHfW6ldHnvckBie3OjeR?=			M{jxWmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJIlvKEOYMTDj[YxteyCkeTDHRWw1KHS{YX7zZYN1cX[jdHnvckBie3OjeTDh[pRmeiB{NDDodpMtKEWFNUC9NE4xOyEQvF2=	NFmzeIwyPzVyN{KyOS=>
CV1 cells	NW\sZYZvTnWwY4Tpc44h[XO\|YYm=			NFHTN\|lC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iQ2[xJINmdGy\|IHL5JJJm[2WydH;yJJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NF0xNjNyODFOwG0>	Mn:zNVgxOjlzN{i=
CV1 cells	NFrHXHJHfW6ldHnvckBie3OjeR?=			MoPlRYdwdmm\|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEhcW5iQ2[xJINmdGy\|IHL5JJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NF0xNjNyODFOwG0>	M{fpdVE4OTJ7N{K1
HEK293 cells	Ml;GSpVv[3Srb36gZZN{[Xl?			MVPB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBz\WOncITvdkBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIJ6KEeDTESgeJJidnOjY4TpeoF1cW:wIHHzd4F6NCCHQ{WwQVAvODN3IN88US=>	M13jZVE4Ojl{NkC2
NIH3T3 cells	NGfLO\|BHfW6ldHnvckBie3OjeR?=			NYT6bYhjSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIF7JTFNVOyClZXzsd{BjgSCJQVy0JJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NF0xNjN{IN88US=>	MXexO\|YzPDd5Nx?=
HEK293 cells	NYnQNWVyTnWwY4Tpc44h[XO\|YYm=			NX63R\|J6SWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCkeTDHRWw1KHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1yLkG5JO69VQ>?	MVexPFAzQTF5Nh?=
HEK293 cells	M2n3ZmZ2dmO2aX;uJIF{e2G7			NVfnXXJlSWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDhVFIh\2WwZTDpcoR2[3Srb36sJGVEPTB;MD6xNkDPxE1?	M{PtclE5ODJ7MUe2
HEK293 cells	M1zGNmZ2dmO2aX;uJIF{e2G7			NHraR2xC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCrbjDISWszQTNiY3XscJMh[nliR1HMOEB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5yNEWg{txO	NF\FUIMyQDJ7MU[0OS=>
HepG2 cells	M4DyeWZ2dmO2aX;uJIF{e2G7			M3jjNmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmGucHjhJIxq\2GwZDDibY5lcW6pIHTvcYFqdiCneIDy[ZN{\WRiaX6gbJVu[W5iSHXwS\|Ih[2WubIOgZ48ufHKjboPm[YN1\WRid3n0bEBI[Wx2IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjB\|OTFOwG0>	NXTzbZhSOTh6M{W3NVk>
RAW264.7 cells	NYfKNXRuTnWwY4Tpc44h[XO\|YYm=			M4jD[XN2eHC{ZYPzbY9vKG:oIFzQV{9KTk5vZ3HtcYEue3SrbYXsZZRm\CCQTzDwdo9lfWO2aX;uJIlvKG2xdYPlJHJCXzJ4ND63JINmdGy\|LDDFR\|UxRTF5LkWg{txO	M1\MSlE5QDB7M{K1
BL21 cells	NXLYRnNQTnWwY4Tpc44h[XO\|YYm=			MV;EbZNxdGGlZX3lcpQhd2ZicnHkbY8hdGGkZXzl[EAzMFNrLTiyMYJmdnqxeXytdIhmdnmuYX3pco8qNTNve{StX\|EtOS2maYTybZRqdy1{LTi1MY1mfGi7bD2yMZBp\W67bD3vfIF7d2xvND35cEku\XSqb4j5YU1xcGWweXz9MZBzd3Crb37pZ{Bi[2mmIH\yc40hT1OWLX\1d4VlKGi3bXHuJHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJINmdGy\|IHL5JJNkcW62aXzsZZRqd25icILvfIlucXS7IHHzd4F6NCCHQ{WwQVAvPDVizszN	MWmxPVM1QTF5Nh?=
BHK21 cells	MXLGeY5kfGmxbjDhd5NigQ>?			NYPJU\|J3SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIFLIT\|IyKGOnbHzzJIF{e2W\|c3XkJIF{KFOHQWCgZYN1cX[rdImgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;MD60OUDPxE1?	NHXN[GEyQTN2OUG3Oi=>
HepG2/C3A cells	M3q5W2Z2dmO2aX;uJIF{e2G7			Mn;iRYN1cX[jdHnvckBw\iCqdX3hckBRWEGUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwLX3l[IlifGWmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCrbjDoeY1idiCKZYDHNk9EO0FiY3XscJMh[29vdILhcpNn\WO2ZXSge4l1cCCodYPl[EBI[Wx2LVzCSEBjgSClb4TyZY5{\mWldHnvckBie3OjeTygSWM2OD1yLkCwN\|gh\|ryP	NGD5XnAyPzRyM{[4PC=>
HepG2 cells	MljjSpVv[3Srb36gZZN{[Xl?			NFr4N21C\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCneIDy[ZN{\WRiaX6gbJVu[W5iSHXwS\|Ih[2WubIOgZZN{\XO\|ZXSgZZMhcW6mdXP0bY9vKG:oIILlZ4VxfG:{IITyZY5{[WO2aY\heIlwdiCkeTDy[ZBwenSncjDn[Y5mKGG\|c3H5JJJmdGG2aY\lJJRwKGOxboTyc4wtKEWFNUC9NE4xPSEQvF2=	M2OzWVE5PjJ3NUW5
COS1 cells	MV3GeY5kfGmxbjDhd5NigQ>?			NXTVXmFVSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBz\WOxbXLpcoFvfCCSUFHS[4FudWFiZYjwdoV{e2WmIHnuJGNQWzFiY3XscJMh[29vZYjwdoV{e2mwZzDHRWw1KGG\|c3Xzd4VlKGG\|IITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR\|UxRTBwMEKg{txO	NVvo[3VVOTl3MEe4OlE>
HepG2 cells	MU\GeY5kfGmxbjDhd5NigQ>?			MUPB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hUGWyR{KgZ4VtdHNiYomgS2FNPCC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;MD6yNlMh\|ryP	MmTKNVg{QTR7MEe=
CV1 cells	M4DYOWZ2dmO2aX;uJIF{e2G7			MUPB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDsbYdidmRiYnnu[Ilv\yCmb33hbY4h\XiycnXzd4VlKGmwIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JGNXOSClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKG[3c3XkJGdidDRvRFLEJIJ6KHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1yLkCzN{DPxE1?	MX:xPFgzPjJyNR?=
CV1 cells	M3exUWZ2dmO2aX;uJIF{e2G7			NWn6cGszSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUYXzwbIEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHX4dJJme3OnZDDpckBi\nKrY3HuJIdz\WWwIH3vcotmgSCFVkGgZ4VtdHNiY3:teJJidnOoZXP0[YQhf2m2aDDmeZNm\CCJYXy0MWRDTCCkeTD0doFve2GldHn2ZZRqd25iYYPzZZktKEWFNUC9N{41PiEQvF2=	M1O0OlE5QDJ4MkC1
U2OS cells	M4j3OWZ2dmO2aX;uJIF{e2G7			MnK4RYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT\2GvbXGgbY4hXTKRUzDj[YxteyCkeTD0doFve2GldHn2ZZRqd25iYYPzZZktKEWFNUC9NE4xOiEQvF2=	Mn;WNVg{Ojl5NUG=
Hep G2 cells	MmPPSpVv[3Srb36gZZN{[Xl?			NETEWWFC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZUBtcWejbnSgZolv\GmwZzDkc41icW5iZYjwdoV{e2WmIHnuJIh2dWGwIFjldEBIOiClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKEejbEStSGJFKGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlA1KM7:TR?=	NE\ESpMyQTB3M{e3Oi=>
HeLa cells	NF63fmJHfW6ldHnvckBie3OjeR?=			MYXB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBtcWejbnSgZolv\GmwZzDkc41icW5iZYjwdoV{e2WmIHnuJIh2dWGwIFjlUIEh[2WubIOgZ48ufHKjboPm[YN1\WRid3n0bEBI[Wx2LVTCSEBie3Onc4Pl[EBieyC2cnHud4NzcXC2aX;uZYwh[WO2aY\heIlwdiCkeTDHZYw1KHKnc4DvcpNmKGWuZX3lcpQu\HKrdnXuJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjBzNTFOwG0>	M4PiO\|E6Ojd3OU[z
COS1 cells	MUHGeY5kfGmxbjDhd5NigQ>?			NVrxcHpYSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEhemWlZYD0c5Ih\XiycnXzd4VlKGmwIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JGNQWzFiY3XscJMh[29vdILhcpNn\WO2ZXSge4l1cCCodYPl[EB6\WG\|dDDHZYw1NUSERDDifUB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5yMjFOwG0>	NX;KRXd3OTl3M{C2PFE>
U2OS cells	MX\GeY5kfGmxbjDhd5NigQ>?			NVzac\|BRSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIGWyU3Mh[2WubIOgZpkhdHWlaX\ldoF{\SC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;MD6wOUDPxE1?	M2LHeVE6PTd2MEW2
HepG2 cells	MlrhSpVv[3Srb36gZZN{[Xl?			M13nd2Fod26rc4SgZYN1cX[rdImgZZQhT0GOND30ZYdo\WRiaIXtZY4hWFCDUnfhcY1iKGyrZ3Hu[EBjcW6maX7nJIRwdWGrbjDlfJBz\XO\|ZXSgbY4hcHWvYX6gTIVxTzJiY3XscJMh[XO\|ZYPz[YQh[XNicnXj[ZB1d3JidILhcpNi[3SrdnH0bY9vKGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlA{QSEQvF2=	MX[xPVc4PTF4OR?=
HepG2 cells	M4LiUGZ2dmO2aX;uJIF{e2G7			M1f3[WFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCKZYDHNkBk\WyuczDifUBISUx2IITyZY5{[WO2aY\heIlwdiCjc4PhfUwhTUN3ME2wMlIzOyEQvF2=	NUDmXHNQOTl5OEO0OFQ>
COS7 cells	M1rFZWZ2dmO2aX;uJIF{e2G7			NETDc4JC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJJJm[2:vYnnuZY51KFCSQWLnZY1u[TJiTFLEJIV5eHKnc4Pl[EBqdiCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDDU3M4KGOnbHzzJINw\XiycnXzd4lv\yCJQVy0JIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5zIN88US=>	MmfvNlAyOzh5NkK=
COS7 cells	MX\GeY5kfGmxbjDhd5NigQ>?			M1jrXmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gdoVkd22kaX7hcpQhWFCDUnfhcY1iOSCOQlSg[ZhxemW\|c3XkJIlvKGGocnnjZY4h\3KnZX6gcY9vc2W7IFPPV\|ch[2WubIOgZ49mgHC{ZYPzbY5oKEeDTESgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NF0xNjB\|IN88US=>	MXKyNFE{QDd4Mh?=
HEK cells	MoXJSpVv[3Srb36gZZN{[Xl?			NUi4bWROSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBISUx2LYTh[4dm\CCSUFHSZYxxcGFiY3jpcYVzcWNicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGhGUyClZXzsd{BjgSC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;MUCuOVgh\|ryP	MYSyNFI6QTJzNB?=
HEK cells	M{LmOGZ2dmO2aX;uJIF{e2G7			MWLB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIFfBUFQufGGpZ3XkJHBRSVKpYX3tZUBkcGmvZYLpZ{Bz\WOncITvdkBmgHC{ZYPz[YQhcW5iSFXLJINmdGy\|IHL5JJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NF0xNjB\|NTFOwG0>	NYDqZZlPOjB{OUmyNVQ>
3T3L1 cells	NUn1ZWkxTnWwY4Tpc44h[XO\|YYm=		NWPtdWxCPyCmYYnz	NF6wcmdKdmS3Y4Tpc44hd2ZiYXTpdI9o\W6nc3nzJIlvKG2xdYPlJFNVO0xzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIxqeGmmIHHjZ5VufWyjdHnvckBi\nSncjC3JIRigXNiYomgU4ltKHKnZDDPJJN1[WmwaX7n	Moi2NlA2Ojd7Nkm=
CHO-K1 cells	Ml7GSpVv[3Srb36gZZN{[Xl?			NVHmcohMWGG{dHnhcEBi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZU1NSkRiZYjwdoV{e2WmIHnuJGNJVy2NMTDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIFfBUFQh[XO\|ZYPz[YQh[XNibIXjbYZmemG\|ZTDhZ5Rqfmm2eTDifUB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5zIN88US=>	MUiyNFUzPzl4OR?=
HEK293T cells	NIWwTGZHfW6ldHnvckBie3OjeR?=	M3rRU\|Eh\|ryP	NYnOeWhMOjRiaILz	NGr0ZWdR[XK2aXHsJIFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hMWxDTCCneIDy[ZN{\WRiaX6gTGVMOjl\|VDDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhemWlZYD0c5IhfHKjboPhZ5RqfmG2aX;uJIF1KDFidV2gZYZ1\XJiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=>	NGS5WFYzOTB\|MEK2Ny=>
CV1 cells	NF65N4pHfW6ldHnvckBie3OjeR?=			NYD4R4poXHKjboPhZ5RqfmG2aX;uJI9nKEejbESt[pV{\WRiaIXtZY4hWFCDUnfhcY1iKESQQTDibY5lcW6pIHTvcYFqdiCneIDy[ZN{\WRiaX6gZYZzcWOjbjDndoVmdiCvb37r[ZkhS1ZzIHPlcIx{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlEh\|ryP	M{\TTlIyOTF{N{i0
HEK293 cells	NY\4cHhzTnWwY4Tpc44h[XO\|YYm=		NXPKd3hEOTZidH:gNlAhcHK\|	Ml36WJJidnOjY4TpeoF1cW:wIH;mJGdidDRvZoXz[YQhcHWvYX6gVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZYZ1\XJiMU[geI8hOjBiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkC0N{DPxE1?	M4PMT\|IyOTJ6NkCw
HepG2 cells	M{PyVGZ2dmO2aX;uJIF{e2G7	M3\aO\|ExKHWvb3yvUC=>	MlPiNlQhcHK\|	MYDJcoNz\WG\|ZTDpckBodHWlb4PlJINwdnO3bYD0bY9vKGmwIHj1cYFvKEincFeyJINmdGy\|IHH0JFExKHWvb3yvUEBi\nSncjCyOEBpenNicnXsZZRqfmVidH:gZ49vfHKxbB?=	NXq4e4dGOjF{NU[3OFg>
3T3L1 cell	M{fERmZ2dmO2aX;uJIF{e2G7	NH3NemMyKHWP		MV3JcoR2[3Srb36gc4YhdW:3c3WgN3Q{VDFiY3XscEBlcW[oZYLlcpRq[XSrb36gZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iYXPjeY12dGG2aX;uJI9nKGmwdILhZ4VtdHWuYYKgcIlxcWRiZILvdIxmfCCjdDCxJJVOKGK7IF;pcEBz\WRiTzDzeIFqdmmwZx?=	M1jub\|IyPDBzMUG4
CV1 cells	MWPGeY5kfGmxbjDhd5NigQ>?		M1\0ZVQxKGh?	NHzUZXFC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZU1NSkRiZYjwdoV{e2WmIHnuJGNXOSClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKEejbESgZYZ1\XJiNECgbJJ{KGK7IHz1Z4ln\XKjc3WgZoF{\WRidILhcpNi[3SrdnH0bY9vKGG\|c3H5MEBGSzVyPUCuNUDPxE1?	NUjJW2xkOjF3MUWwOlM>
HepG2 cells	M1ruS2Z2dmO2aX;uJIF{e2G7			MULB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBz\WOncITvdkBmgHC{ZYPz[YQhcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYomgVHBTTS2udXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTB;MD6wNUDPxE1?	NXnsZVNyOjF2OEK0OFY>
HepG2 cells	MlzKSpVv[3Srb36gZZN{[Xl?			MnyxWJJidnOjY4TpeoF1cW:wIH;mJIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hcHWvYX6gTIVxTzJiY3XscJMh[29vdILhcpNn\WO2ZXSge4l1cCCSUGLFN{1VUy2OdXOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR\|UxRTBwMEWg{txO	NF;GRoczOTR3MES2PC=>
COS7 cells	MWjGeY5kfGmxbjDhd5NigQ>?			MWXNc4R2dGG2aX;uJI9nKGi3bXHuJHBRSVKpYX3tZU1NSkRiZYjwdoV{e2WmIHnuJIFnemmlYX6g[5Jm\W5ibX;ub4V6KEORU{egZ4VtdHNiY3:teJJidnOoZXP0[YQhf2m2aDDHZYw1KGG\|c3Xzd4VlKGG\|IHHjeIl3[XSrb36gc4YhfHKjboPhZ5RqfmG2aX;uJIFkfGm4aYT5JIJ6KGy3Y3nm[ZJie2ViYYPzZZktKEWFNUC9NE4xPDNizszN	MVGyNVg4OzB5MB?=
COS-1 cells	NYDmXWZDTnWwY4Tpc44h[XO\|YYm=		MXuyOEBpenN?	Mke0RYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT\2GvbXGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKGW6cILld5Nm\CCrbjDDU3MuOSClZXzsd{Bi\nSncjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nLXLhd4VlKGy3bXnuc41mfHKrYzDhcoFtgXOrczygSWM2OD1yLkC0PEDPxE1?	M3XIUFIzODVzMEW0
COS1 cells	NGXDcmxHfW6ldHnvckBie3OjeR?=		NXq4blR5OjRiaILz	NUD3PGU2XHKjboPhZ5RqfmG2aX;uJI9nKGi3bXHuJIZ2dGxibHXu[5RpKFCSQWLnZY1u[SCneIDy[ZN{\WRiaX6gR29UOSClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKFK[UnHsdIhiKGGodHXyJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5zMjFOwG0>	NVvrV5BDOjJzOUezPVY>
MG-63 cells	MV3GeY5kfGmxbjDhd5NigQ>?			M{G1T2Fod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCPRz22N{Bk\WyuczDifUBz\XCxcoTldkBo\W6nLXLhd4VlKHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1yLkCxNUDPxE1?	NGDN[2czOjJ{NU[0NS=>
COS1 cells	MnS1SpVv[3Srb36gZZN{[Xl?			MnLBRolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjD3bYxlKHS7cHWgVHBCWmejbX3hJGxDTCCneIDy[ZN{\WRiaX6gR29UOSClZXzsd{Bkdy2neIDy[ZN{cW6pIFfBUFQh[nlic3PpcpRqdGyjdHnvckBxem:6aX3peJkh[XO\|YYm=	NULRZnhLOjJyN{C2NFQ>
MG-63 cells	MYjGeY5kfGmxbjDhd5NigQ>?		MUiyOEBpenN?	NIfxNHBOd2S3bHH0bY9vKG:oIH\1cIwudGWwZ4ToJIh2dWGwIIDTS\|Uu\nW\|ZXSgVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCPRz22N{Bk\WyuczDjc{1mgHC{ZYPzbY5oKHCJVj3QNk1RWFKHIHHmeIVzKDJ2IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[mG\|ZXSgeJJidnOjY4TpeoF1cW:wIHHzd4F6NCCHQ{WwQVAvODFzIN88US=>	NFTDc5czOjd{N{S0PC=>
Ac2F cells	MXTGeY5kfGmxbjDhd5NigQ>?	M{jSWVAvOSC2bzCxNEDPxE1?	Mn7zOkBpenN?	MmLnRYdwdmm\|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEhcW5icnH0JGFkOkZiY3XscJMh[XO\|ZYPz[YQh[XNibIXjbYZmemG\|ZTDhZ5Rqfmm2eTDheEAxNjFidH:gNVAhfU1iYX\0[ZIhPiCqcoOgZpkhemWyb4L0[ZIh\2WwZTDhd5NigQ>?	NUfjWVhmOjJ6MUmxPVA>
293H DA cells	MmfrSpVv[3Srb36gZZN{[Xl?		M{fmOFE3KGh?	NH\UbYFC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCOQlSgbY4hcHWvYX6gNlk{UCCGQTDj[YxteyCjZoTldkAyPiCqcoOgZpkhXFJvRmLFWEBi[3SrdnH0bY9vKHKncH;yeIVzKGG\|c3H5MEBGSzVyPUCuNFAzPCEQvF2=	NH\ZO2UzOjV6Mkm3Ny=>
3T3L1 cells	NYK4XWpDTnWwY4Tpc44h[XO\|YYm=	MnHTNVAhfU1?		MUnJcoNz\WG\|ZTDpckBi\Gmyb37lZ5RqdiCvUl7BJIxmfmWuczDpckBVVk[jbIDoZU1qdmS3Y3XkJI1wfXOnIEPUN2wyKGOnbHzzJJBz\XS{ZXH0[YQh[XRiMUCgeW0h[mWob4LlJHRPTi2jbIDoZUBkcGGubHXu[4UhemWuYYTpeoUhfG9iY3;ueJJwdA>?	M3PSPFIyQDVzMEi5
HepG2 cells	NFH1SYlHfW6ldHnvckBie3OjeR?=	NHXSZ4oyOCC3TR?=	M{DPdFI1KGh?	NUnnZXVEWmWmdXP0bY9vKG:oIHfseYNwe2ViY3;ud5VueHSrb36gbY4hcW6\|dXzpck1z\XOrc4ThcpQhcHWvYX6gTIVxTzJiY3XscJMh[XRiMUCgeW0h[W[2ZYKgNlQhcHK\|IHL5JIdtfWOxc3Wgc5hq\GG\|ZTDt[ZRpd2RiaX6gdJJme2WwY3Wgc4YhOjJwMjDtUUBw\iCpbIXjc5Nm	NGDXTm4zOzB{NUK0OC=>
HepG2 cells	NIfIeWNHfW6ldHnvckBie3OjeR?=	NVTMSYZ{OTBidV2=	M2fFUVI1KGh?	M33DenJm\HWldHnvckBw\iCpbIXjc5NmKGOxboP1cZB1cW:wIHnuJIlve3WuaX6tdoV{cXO2YX70JIh2dWGwIFjldGczKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDncJVkd3OnIH;4bYRie2VibXX0bI9lKGmwIIDy[ZNmdmOnIH;mJFAvOSC3TTDv[kBqdnO3bHnu	NIPaOHYzOzB{NUK0OC=>
THP1 cells	M3KyOmZ2dmO2aX;uJIF{e2G7	M4rtWlExOCC3TR?=	NI\veFQ{KGi{cx?=	NGTZRVZVemGwc3HjeIl3[XSrb36gc4YhWFCDUnfhcY1iKGmwIHj1cYFvKFSKUEGgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hVFCVLXnu[JVk\WRiTVPQNUBuWk6DIHX4dJJme3Orb36gZZQhOTByIIXNJJBz\WmwY4XiZZRm\CCob4KgN{BpenNicILpc5IhfG9iTGDTJINp[WyuZX7n[UBu\WG\|dYLl[EBi\nSncjCxPEBpenNiYomgVnQuWEOUIHHuZYx6e2m\|IILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;s	MUeyNlk{PDV\|Nx?=
THP1 cells	M4HJN2Z2dmO2aX;uJIF{e2G7	NFnhTW8yODBidV2=	NVfWeZlIOyCqcoO=	MlL3WJJidnOjY4TpeoF1cW:wIH;mJHBRSVKpYX3tZUBqdiCqdX3hckBVUFBzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJGxRWy2rbnT1Z4VlKEmONjDtVm5CKGW6cILld5Nqd25iYYSgNVAxKHWPIIDy[Ylv[3WkYYTl[EBnd3JiMzDodpMheHKrb4KgeI8hVFCVIHPoZYxt\W6pZTDt[YF{fXKnZDDh[pRmeiBzODDodpMh[nliUmStVGNTKGGwYXz5d4l{KHKnbHH0bZZmKHSxIIXueJJm[XSnZDDjc451em:u	NVz2PZlFOjJ7M{S1N\|c>
HepG2 cells	NIHvTXJHfW6ldHnvckBie3OjeR?=			M3\5dnRz[W6\|YXP0bZZifGmxbjDv[kBISUx2LX\1d4VlKFCSQWLnZY1u[SCuaXfhcoQh[mmwZHnu[{Bld22jaX6geJJidnOoZXP0[YQhcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvOSEQvF2=	NXXoUZp4OjJ7M{S1N\|c>
HepG2 cells	MVLGeY5kfGmxbjDhd5NigQ>?		M3O2c\|IxKGh?	NWHHbYxpSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBISUx2LX\1d4VlKFCSQWLnZY1u[SCuaXfhcoQh[mmwZHnu[{Bld22jaX6g[ZhxemW\|c3XkJIlvKEincFeyJINmdGy\|IHHmeIVzKDJyIHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxRTBwMEKg{txO	NH35N2UzOjB6MUmzNi=>
BL21 DE3 cells	M2GyXmZ2dmO2aX;uJIF{e2G7			NFPCc3JFcXOybHHj[Y1mdnRib3[gX\|NJZXKxc3nncIl1[XqxbnWg[pJwdSCQLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5iUGDBVodidW2jIHzp[4Fv\CCkaX7kbY5oKGSxbXHpckBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJGRGOyClZXzsd{BjgSC\|Y3nueIltdGG2aX;uJJBzd3irbXn0fUBie3OjeTygT4k:OC5yN{Sg{txO	NGTpXlEzOjB6MUmzNi=>
human L02 cells	Ml7GSpVv[3Srb36gZZN{[Xl?			NXjK[I5kSWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFvTFLEJIV5eHKnc4Pl[EBqdiCqdX3hckBNODJiY3XscJMh[29vZYjwdoV{e2mwZzDwS2w{NVOYNECtS2FNPCCjZoTldkAzPCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIJie2WmIITyZY5{[WO2aY\heIlwdiCjc4PhfUwhTUN3ME2wMlkh\|ryP	M1zEb\|I{OTh4M{C3
HepG2 cells	NGTTdoRHfW6ldHnvckBie3OjeR?=		NWTWU21ZOjBiaB?=	M13HUXRz[W6\|YXP0bZZifGmxbjDv[kBISUx2LX\1d4VlKGi3bXHuJHBRSVKpYX3tZUBtcWejbnSgZolv\GmwZzDkc41icW5iZYjwdoV{e2WmIHnuJGhmeEd{IHPlcIx{KGGodHXyJFIxKGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5yM{mg{txO	NX\mZYw4OjNzN{GwOFU>
HEK293 cells	M3fKS2Z2dmO2aX;uJIF{e2G7	MYGxNEDPxE1?		M17wcHRz[W6\|YXP0bZZifGmxbjDv[kBRWEGUZ3HtcYEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJINwNXS{YX7z[oVkfGWmIIfpeIghSVB{LWDQVmUh[XRiMUCgeW0h[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5	NWfvSYlYOjN{N{O1NVk>
HEK293 cells	MmjMSpVv[3Srb36gZZN{[Xl?			NE\md\|BC\2:waYP0JIF1KGi3bXHuJHBRSVKpYX3tZUBNSkRiZYjwdoV{e2WmIHnuJIh2dWGwIFjFT\|I6OyClZXzsd{Bkd3S{YX7z[oVkfGWmIIfpeIghT0GOND3MeYMh[XO\|ZYPz[YQh[XNidILhcpNkemmydHnvcoFtKGGldHn2ZZRqd25iYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODB2IN88US=>	Ml6wNlMzQDZ5OEe=
HEK293 cells	MVrGeY5kfGmxbjDhd5NigQ>?		Mn;VNlQhcA>?	MXPUdoFve2GldHn2ZZRqd25ib3[gS2FNPCCGQlSt[pV{\WRiaIXtZY4hWFCDUnfhcY1iNUyERDDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTB;MD6xJO69VQ>?	MoHVNlMzQTR6M{C=
HEK293 cells	M4ruSGZ2dmO2aX;uJIF{e2G7		NIfMVVQ1QCCqcoO=	MV\B[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHPveJJidnOoZXP0[YQhf2m2aDDQVHJGgDRvVFutcJVkKGG\|c3Xzd4VlKGG\|IHHjeIl3[XSrb36gc4YhdHWlaX\ldoF{\SCjY4Tpeol1gSCvZXHzeZJm\CCjZoTldkA1QCCqcoOgZpkhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxRTR\|LkexJO69VQ>?	M4S3SFI{OjZ3OES0
HepG2 cells	Mnu1SpVv[3Srb36gZZN{[Xl?			NV7kcXR5SWexbnnzeEBi[3Srdnn0fUBifCCJQVy0MYZ2e2WmIGDQRXJo[W2vYTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBpfW2jbjDI[ZBIOiClZXzsd{BjgSC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;MD6wNUDPxE1?	MXyyN\|UxOjJzMh?=
HepG2 cells	NV7pV49DTnWwY4Tpc44h[XO\|YYm=			NWXPWXd3SWexbnnzeEBi[3Srdnn0fUBifCCJQVy0MYZ2e2WmIGDQRXJo[W2vYTDNOFY{SSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYomgeJJidnOjY4TpeoF1cW:wIHHzd4F6NCCHQ{WwQVAvODB{IN88US=>	NF\qSWwzOzVyMkKxNi=>
L6 cells	M4j0NmZ2dmO2aX;uJIF{e2G7		NWDxdYp1OjRiaILz	NUH1dIxNUW6mdXP0bY9vKG:oIHfseYNwe2VidYD0ZYtmKGmwIILheEBNPiClZXzsd{BxfWy\|ZXSge4l1cCCFMUSt[IVwgHliZ3z1Z49{\SCjZoTldkAzPCCqcoOgbY4heHKnc3XuZ4Uhd2ZiaX7zeYxqdixiRVO1NF01NjR7IN88US=>	Ml23NlM6QTJ6NkK=
L6 cells	MmfxSpVv[3Srb36gZZN{[Xl?		M4LhUlE3KGi{cx?=	M1GzV2lv[3KnYYPlJIlvKDJvW{PIYU1l\W:6eXfseYNwe2VidYD0ZYtmKGmwIILheEBNPiClZXzsd{Bi\nSncjCxOkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yCjbnHsfZNqeyxiRVO1NF01NjhizszN	NUTSV5JiOjR6MUO3N\|g>
DU145 cells	MkD2R5l1d3SxeHnjbZR6KGG\|c3H5		MXy0PEBpenN?	MYjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCHQ{WwQVE3KM7:TR?=	NX3RcYZJOjR7OU[xOFM>
PC3 cells	NXH4T\|diS3m2b4TvfIlkcXS7IHHzd4F6		NGfNOmI1QCCqcoO=	M1O3OmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCHQ{WwQVIxNjNizszN	M1L3WVI1QTl4MUSz
MDA-MB-231 cells	NF7wcFlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVTqeJdUOjRiaILz	NUjHbm9sT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG\|c3H5MEBGSzVyPUWuNlMh\|ryP	MlL5NlUzPzh{M{[=
HEK293 cells	NXnOVYNVTnWwY4Tpc44h[XO\|YYm=			MY\B[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjBzIN88US=>	NXnkdJg6OjV\|MEW2PFg>
HepG2 cells	M1HWVWZ2dmO2aX;uJIF{e2G7		M4\iV\|IxKGi{cx?=	M3PnbnRz[W6\|YXP0bZZifGmxbjDv[kBRWEGUIITyZY5{\mWldHXkJIlvKGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFIxKGi{czDifUBRWEGULXz1Z4ln\XKjc3WgZZN{[XluIFXDOVA:OS54IN88US=>	M{DqbVI2PDN5M{C0
HEK293 cells	M{XB[mZ2dmO2aX;uJIF{e2G7		NH7xeIYzPCCqcoO=	MUfUdoFve2GldHn2ZZRqd25ib3[gVHBCWmejbX3hJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYm=	MlzpNlU1PDJ\|MkK=
HepG2 cells	NULodnlpTnWwY4Tpc44h[XO\|YYm=			MVPB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIFfBUFQuWFCDUnfhcY1iKGyrZ3Hu[EBjcW6maX7nJIRwdWGrbjDlfJBz\XO\|ZXSgbY4hcHWvYX6gTIVxTzJiY3XscJMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBGSzVyPUCuNFM6KM7:TR?=	MlmwNlU1PjJ{OEG=
HEK293 cells	Mn\MSpVv[3Srb36gZZN{[Xl?		NFeye4czPCCqcoO=	NWDLNGV2SWexbnnzeEBi[3Srdnn0fUBifCCvb4Xz[UBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{Bkdy2neIDy[ZN{cW6pIIfpeIghT2GuNDDy[ZBwenSncjD2[YN1d3JiYX\0[ZIhOjRiaILzJIJ6KGS3YXytcJVkcW[ncnHz[UBz\XCxcoTldkBie3OjeTygSWM2OD1yLkCzJO69VQ>?	MUiyOFk2PTh6OR?=
HepG2 cells	MWPGeY5kfGmxbjDhd5NigQ>?		NFzqNIYzOCCqcoO=	Ml;hRYdwdmm\|dDDhZ5Rqfmm2eTDheEBISUx2LVTORUBjcW6maX7nJIRwdWGrbjDmeZNm\CCqdX3hckBRWEGUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHX4dJJme3OnZDDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyC{ZXPldJRweiC2cnHud4FkfGm4YYTpc44hcW6ldXLheIVlKG[xcjCyNEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODRizszN	NWPTVnBLOjV2OUexN\|I>
HepaR cells	MUTGeY5kfGmxbjDhd5NigQ>?		NV3yR4hFOSCmYYm=	NU[5[2tSSWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFiaX6gbJVu[W5iSHXwZXIh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iSF3HR3MzKGenbnWg[ZhxemW\|c3nvckBifCBzIIXNJIlv[3WkYYTl[EBnd3JiMTDkZZkh[nlicYXhcpRqfGG2aY\lJHBEWiCvZYToc4QhemWuYYTpeoUhfG9idX70doVifGWmIHPvcpRzd2x?	NH;SXVIzPTR7N{GzNi=>
HepaR cells	MYLGeY5kfGmxbjDhd5NigQ>?	MlizNUB2VQ>?	M1rVflEh\GG7	NEP2NIpC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCrbjDoeY1idiCKZYDhVkBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCDTlfQWGw1KGenbnWg[ZhxemW\|c3nvckBifCBzIIXNJIlv[3WkYYTl[EBnd3JiMTDkZZkh[nlicYXhcpRqfGG2aY\lJHBEWiCvZYToc4QhemWuYYTpeoUhfG9idX70doVifGWmIHPvcpRzd2x?	NFrhdoMzPTR7N{GzNi=>
HepaR cells	M1rWTWZ2dmO2aX;uJIF{e2G7	M{X3b\|EhfU1?	NYWyPVV{OSCmYYm=	M3XVb2Fod26rc4SgZYN1cX[rdImgZZQhWFCDUnfhcY1iKGmwIHj1cYFvKEincHHSJINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKE[DQmCxJIdmdmViZYjwdoV{e2mxbjDheEAyKHWPIHnuZ5Vj[XSnZDDmc5IhOSCmYYmgZpkheXWjboTpeIF1cX[nIGDDVkBu\XSqb3SgdoVt[XSrdnWgeI8hfW62cnXheIVlKGOxboTyc4w>	MlrKNlU1QTdzM{K=
HEK293 cells	NWX5RXF4TnWwY4Tpc44h[XO\|YYm=	MYqxNEDPxE1?	NH34WI0zPCCqcoO=	Mk\yWJJidnOjY4TpeoF1cW:wIH;mJHBRSVJvZ3HtcYEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF1KDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk>	NHPyV4ozPDh7MEC5NC=>
C2C12 cells	M2DsSGZ2dmO2aX;uJIF{e2G7	NHXQeHU{OCEQvF2=	Ml[4NkBp	NYD6cFBRUW6mdXP0bY9vKG:oIEKt[IVwgHlvW{PIYU1odHWlb4PlJJVxfGGtZTDpckBud3W\|ZTDDNmMyOiClZXzsd{BifCB\|MDD1UUBi\nSncjCyJIhzeyCkeTDsbZF2cWRic3PpcpRqdGyjdHnvckBkd3WwdHnu[{BidmGueYPpdy=>	MYqyOVg{PTV\|Nx?=
MCF7 cells	MlGxSpVv[3Srb36gZZN{[Xl?		NEPTPHkyPiCq	MYDB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTD0doFve2[nY4Tl[EBqdiCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFE3KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5yOEeg{txO	MUiyOlIzPjR7MB?=
HEK293 cells	NU[0T\|c4TnWwY4Tpc44h[XO\|YYm=	NUXmXpRrOTBizszN	M1\lfVI1KGh?	MVjB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZN{\XO\|ZXSgZZMhemWlZYD0c5IhfHKjboPhZ5RqfmG2aX;uJIF1KDFyIIXNJIlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=>	MlHZNlY{QDR{OE[=

... Click to View More Cell Line Experimental Data

Protocol

References

Solubility (25°C)

In vitro	DMSO	35 mg/mL (198.67 mM)
	Ethanol	35 mg/mL (198.67 mM)
	Water	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download 4-Methylumbelliferone (4-MU) SDF

Molecular Weight	176.17
Formula	C₁₀H₈O₃
CAS No.	90-33-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00225537	Unknown status	Chronic Hepatitis C\|Chronic Hepatitis B	MTmedical Institute of Health\|The University of Texas Health Science Center at San Antonio\|BioMonde Preparations Limited	September 2005	Phase 2
NCT00225537	Unknown status	Chronic Hepatitis C\|Chronic Hepatitis B	MTmedical Institute of Health\|The University of Texas Health Science Center at San Antonio\|BioMonde Preparations Limited	September 2005	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Related Others Products0

CB-839 ^New

CB-839 is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. Phase 1.
GKT137831 ^New

GKT137831 is a potent, dual NADPH oxidase NOX1/NOX4 inhibitor with Ki of 110 nM and 140 nM, respectivelyl; ~10-fold selectivity towards NOX1, 4 and 5 over NOX2, does not inhibit XO or scavange ROS/RNS.
LB-100 ^New

LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor with IC50s of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells.
Puromycin 2HCl

Puromycin 2HCl is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.
Cyclosporin A

Cyclosporin A is an immunosuppressive agent, binds to the cyclophilin and then inhibits calcineurin with IC50 of 7 nM in a cell-free assay, widely used in organ transplantation to prevent rejection.
Cyclophosphamide Monohydrate

Cyclophosphamide Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA, shown to crosslink DNA, causing strand breakage and inducing mutations.
Ganciclovir

Ganciclovir is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 μM in a cell-free assay.
Calcitriol

Calcitriol is a nonselective vitamin D receptor activator/agonist(VDRA), exhibiting a 10-fold higher vitamin D receptor (VDR) binding affinity(IC50=0.4 nM) than the selective VDRA paricalcitol.
Ribavirin

Ribavirin, a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses.
BAPTA-AM

BAPTA-AM is a selective, membrane-permeable calcium chelator.

Choose Your Country or Region

By Signaling Pathways

By product type

4-Methylumbelliferone (4-MU)

Purity & Quality Control

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download 4-Methylumbelliferone (4-MU) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Related Others Products0

Choose Your Country or Region

By Signaling Pathways

By product type

4-Methylumbelliferone (4-MU)

Purity & Quality Control

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download 4-Methylumbelliferone (4-MU) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Related Others Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)